NEW YORK, Oct 2 (Reuters) - SciClone Pharmaceuticals Inc dropped 18.1 percent in extended trade on Friday after the company said it discontinued the development of its experimental cancer drug following the recommendation by a data safety monitoring committee.
(Reporting by Chuck Mikolajczak) Keywords: MARKETS STOCKS AFTERTHEBELL (Charles.mikolajczak@thomsonreuters.com; +1 646 223 5234; Reuters Messaging:rm://Charles.mikolajczak.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
(Reporting by Chuck Mikolajczak) Keywords: MARKETS STOCKS AFTERTHEBELL (Charles.mikolajczak@thomsonreuters.com; +1 646 223 5234; Reuters Messaging:rm://Charles.mikolajczak.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
